Syncona To Acquire Freeline Therapeutics for $28.3M
Portfolio Pulse from Benzinga Newsdesk
Syncona, a healthcare company focused on founding, building, and funding global leaders in life science, has agreed to acquire Freeline Therapeutics for $28.3 million. Freeline Therapeutics, which may be referred to by its ticker FRLN, is a biotechnology firm specializing in gene therapies.

November 22, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics, a biotechnology company specializing in gene therapies, is being acquired by Syncona for $28.3 million.
The acquisition of Freeline Therapeutics by Syncona is a significant event for FRLN, as it not only provides immediate financial value to shareholders but also aligns the company with a larger entity that has the resources to further develop and market its gene therapies. This is likely to be viewed positively by investors, potentially leading to a short-term increase in FRLN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100